Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Ended

2024-512961-15-00 Residual or Recurrent Grade 2 Glioma With an IDH1 or ID 5 2020-08-05
A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with F… Ended

2024-515379-36-00 Metastatic pancreatic ductal adenocarcinoma 9 2020-08-04
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma Ended

2024-512102-25-00 Neuroblastoma 3 2020-07-29
A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or i… Ended

2023-507236-20-00 Follicular Lymphoma (FL) 9 2020-07-28
PACIFICA: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thro… Ended

2024-515953-52-00 Post-Essential Thrombocythaemia Myelofibrosis 5 2020-07-24
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA) Ended

2024-512731-74-00 multiple myeloma 4 2020-07-03
An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy fo… Ended

2024-513276-17-00 Acute Myeloid Leukemia 3 2020-07-01
CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi… Ended

2023-509089-39-00 Non-Muscle Invasive Bladder Cancer 5 2020-07-01
Tocotrienol and bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial Ended

2024-517075-21-00 Metastatic Colorectal cancer 4 2020-06-26
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended

2023-507419-37-00 Plasma cell myeloma 5 2020-06-25
Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma Ended

2024-512704-20-00 Unresectable and/or metastatic soft-tissue sarcoma afte 4 2020-06-22
A first-in-human clinical study to assess feasibility, safety and antitumor activity of genetically modified T-cells in multiple myeloma Ended

2024-512643-23-00 Multiple myeloma 7 2020-06-22
A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multipl… Ended

2023-508962-14-00 Relapsed/Refractory Multiple Myeloma 5 2020-06-18
Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratifica… Ended

2023-509394-23-00 Stage II melanoma arising from a primary cutaneous site 5 2020-06-12
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha… Ended

2023-506588-32-00 Relapsed and Lenalidomide-Refractory Multiple Myeloma 5 2020-06-12
A study to look at how safe and effective glofitamab plus R-CHOP in ctDNA high-risk people with untreated diffuse large B-cell lymphoma Ended

2023-504994-19-00 Diffuse Large B-Cell Lymphoma 4 2020-06-12
Study comparing two standard treatments as initial metastatic treatment among patients with visceral metastasis of ER+ HER2- breast cancer, … Ended

2024-513005-31-00 Patients with untreated metastatic Estrogen Receptor po 5 2020-06-11
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell… Ended

2023-503591-25-00 Non-small cell lung cancer 5 2020-06-09
RACE-trial: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of t… Ended

2024-516271-32-00 Adenocarcinoma of the gastroesophageal junction (AEG ty 5 2020-06-03
Safety and potential efficacy of combining immunotherapy with chemotherapy and radiation for treatment of borderline resectable, nonresectab… Ended

2024-518173-34-00 Borderline resectable, locally advanced or metastatic p 9 2020-06-02
ADP-A2M4CD8 in advanced cancers Ended

2024-512864-71-00 Urothelial cancer Esophageal cancer Gastric cancer Non 3 2020-05-27
A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients wit… Ended

2024-514933-39-00 Patients with Advanced Tumors and Tenosynovial Giant Ce 7 2020-05-26
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200) Ended

2023-508214-42-00 Previously treated locally advanced and unresectable or 5 2020-05-25